№ files_lp_4_process_1_43787
File format: docx
Character count: 1963
File size: 51 KB
Checklist outlining supporting documentation and procedural submissions required by NYSE American LLC from companies seeking authorization and completion of an initial securities listing on the exchange.
Organization:
NYSE American LLC
Document type:
Checklist
Subject:
Initial listing application documentation requirements
Purpose:
Submission of supporting materials for authorization to list securities
Applicable exchange:
NYSE American
Related process:
Initial public offering (IPO) or other listing types
Required submissions:
Listing application forms, shareholder evidence, legal letters, corporate governance documents, securities registration filings
Regulatory references:
U.S. Securities and Exchange Commission filings (Form 8-A, Form 10, Form 20-F)
Corporate documents referenced:
Charter, bylaws, committee charters, code of ethics
Additional confirmations:
CUSIP Bureau confirmation letter, corporate governance affirmations
Special provisions:
Section 110 Letter for foreign private issuers
Submission stages:
Documents required for authorization to list; documents required prior to listing; documents required after listing
Responsible signatory:
Executive officer of the applicant company
Audience:
Companies applying for listing on NYSE American
Jurisdiction:
United States
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
New York, NY
Topic:
Initial Public Offering, Listing Requirements
Document Type:
Official Letter
Organization:
NYSE American LLC
Author:
[Firm Name]
Target Audience:
NYSE American LLC, Company Representatives
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2014
Region / City:
New York, Anytown
Subject:
Corporate Finance
Document Type:
Application
Organization:
ANY CORPORATION
Author:
ANY CORPORATION
Target Audience:
NYSE American LLC, Investors
Effective Period:
January 1, 2014
Approval Date:
Not Provided
Date of Changes:
Not Provided
Agency:
United States Securities and Exchange Commission
Form number:
Form 25
Document type:
Regulatory filing form
Jurisdiction:
United States
Legal basis:
Securities Exchange Act of 1934
Applicable rules:
Rule 12d2-2 (17 CFR 240.12d2-2); Rule 19d-1 (17 CFR 240.19d-1)
OMB control number:
3235-0080
OMB expiration date:
March 31, 2021
Filing system:
EDGAR
Effective delisting period:
10 days after filing
Effective withdrawal of registration period:
90 days after filing
Revision identifier:
SEC 1654 (03-06)
Year:
2025
Region / city:
Australia
Subject:
Oncology, Pharmaceutical Submission
Document Type:
Pharmaceutical Benefits Scheme (PBS) Submission
Organ / Institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
JANSSEN-CILAG PTY LTD
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Ongoing
Approval Date:
Pending
Date of modifications:
N/A
Year:
2025
Region / City:
Uganda
Theme:
Procurement, Health Services, Public Contracts
Document Type:
Pre-Qualification Notice
Authority:
Mulago Specialised Women and Neonatal Hospital
Author:
Not specified
Target Audience:
Providers, Contractors, Suppliers
Period of Validity:
2025-2028
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2024
Region / Country:
Australia
Therapeutic Area:
Gastroenterology
Type of Document:
Regulatory submission / PBAC evaluation
Product:
Budesonide 4 mg suppository (Budenofalk®)
Comparator:
Budesonide 2 mg foam (Budenofalk®), prednisolone suppositories and enemas, hydrocortisone acetate enemas
Regulatory Authority:
TGA (Therapeutic Goods Administration)
Intended Use:
Short-term treatment of mild to moderate ulcerative colitis limited to the rectum
Prescriber Type:
Medical practitioners, Nurse practitioners
PBS Benefit Type:
Unrestricted
Maximum Quantity:
1 pack, 30 units
Treatment Duration:
up to 8 weeks per script
Clinical Evidence:
Phase 3, randomized, double-blind, double-dummy, non-inferiority trial (BUS-4/UCA)
Year:
2025
Region / City:
Windhoek
Subject:
Public Administration, Consultancy, Research
Document Type:
Official Announcement
Institution:
Namibia Institute of Public Administration and Management (NIPAM)
Author:
NIPAM
Target Audience:
Facilitators, Researchers, Consultants, Public Sector Experts
Period of Validity:
Until 10 February 2025
Approval Date:
Not specified
Date of Last Modification:
Not specified
Year:
2011
Regulation:
The Companies Regulations 2011, as amended
Region / Market:
Johannesburg Stock Exchange (JSE)
Document Type:
Regulatory guidance / compliance document
Scope:
Pre-Listing Statements (PLS), Revised Listing Particulars (RLP), Circulars
Language:
English
Applicable Parties:
Issuers and applicants seeking listing on JSE
Requirements:
Disclosure obligations, material contracts, corporate actions
Website Obligation:
Operational website for disclosure compliance
Audience:
Investors, shareholders
Year:
[Year]
Region / City:
Wellington
Topic:
Securities listing and quotation
Document Type:
Application
Organization:
NZ RegCo
Author:
[Issuer Name]
Target Audience:
NZX, securities issuers
Effective Period:
[Date]
Approval Date:
[Date]
Amendment Date:
[Date]
Year:
2023
Region / city:
Australia
Topic:
Oncology, Pharmaceuticals
Document Type:
Resubmission
Institution:
Australian Government, Pharmaceutical Benefits Advisory Committee
Author:
AstraZeneca Pty Ltd.
Target Audience:
Healthcare professionals, regulatory bodies
Effective Period:
Ongoing
Approval Date:
November 2021
Date of Changes:
November 2021
Note:
Year
Note:
Year
Year:
2021
Region / city:
United States
Subject:
COVID-19, Federal Audit Clearinghouse
Document Type:
Memo
Institution:
Department of Education
Author:
Phillip Juengst, Deputy Assistant Secretary
Target Audience:
Grant recipients of the Department of Education
Effective Date:
August 9, 2021
Date of Approval:
August 4, 2021
Questions:
[email protected]
Period of Applicability:
For single audit submissions on or after August 9, 2021
Document Description:
Guidance on how to report subprogram Assistance Listing Numbers (ALNs) with their alphas in the Federal Audit Clearinghouse single audit submission form for Department of Education programs.
Year:
2021
Region / city:
South Africa
Topic:
Financial Instruments, Exchange-Traded Notes
Document Type:
Listing Announcement
Organ / Institution:
FirstRand Bank Limited
Author:
FirstRand Bank Limited
Target Audience:
Investors, Financial Institutions
Period of Validity:
17 August 2021 – 17 August 2026
Approval Date:
17 August 2021
Amendment Date:
None
Year:
2018
Region / city:
Australia
Topic:
Immunisation, Hepatitis B
Document type:
Report
Agency / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Chief Medical Officer
Target audience:
Healthcare professionals, policymakers
Period of validity:
Until 31 December 2019
Date of approval:
June 2018
Date of amendments:
None
Year:
2021
Event:
Expert meeting
Location:
Online
Organization:
UNESCO
Topic:
Intangible cultural heritage, listing mechanisms
Type of document:
Report / Meeting overview
Author:
Rieks Smeets
Target audience:
UNESCO member states, cultural heritage experts
Dates of event:
26–27 May 2021
Time:
13:00–16:00 (Paris time / UTC+2)
Historical period covered:
1960s–2008
Year:
2021
Region / city:
Online
Subject:
Intangible Cultural Heritage
Document type:
Background Paper
Organization:
UNESCO
Author:
UNESCO Secretariat
Target audience:
Experts, States Parties, practitioners in the field of intangible cultural heritage
Duration:
May 2021 – ongoing
Approval date:
Not provided
Amendment date:
Not provided
Year:
2023
Region / City:
Jurupa Valley, California
Topic:
Economic development subsidies, transient occupancy tax, development agreements
Document Type:
Statement of information
Organization / Institution:
City of Jurupa Valley
Author:
Not specified
Target Audience:
General public, stakeholders involved in the development project
Period of Validity:
2023-2043
Approval Date:
September 7, 2023
Amendment Date:
Not specified
Contextual Description:
A statement detailing the economic development subsidies for the proposed development agreement related to the District at Jurupa Valley, including information on public funding, job creation, and tax revenue projections.
Year:
Not specified
Region / City:
Not specified
Subject:
Software Licensing Agreement
Document Type:
Legal Agreement
Organization / Institution:
Schrödinger, L.L.C.
Author:
Schrödinger, L.L.C.
Target Audience:
Licensee, Users
Effective Period:
3 years
Approval Date:
Not specified
Amendment Date:
Not specified
License Type:
Not specified
Year:
2021
Region / City:
California, Arizona
Topic:
Energy Transmission, Public Utilities
Document Type:
Decision
Organization / Institution:
California Public Utilities Commission
Author:
California Public Utilities Commission
Target Audience:
Stakeholders in energy infrastructure and transmission
Effective Period:
N/A
Approval Date:
November 4, 2021
Date of Changes:
N/A